MedWatch

Serious setback for Genmab in DuoBody collaboration

Genmab has suffered a significant setback for one of the early clinical assets being developed in a collaboration with Janssen after a phase I study has been put on clinical hold.

Foto: PR Genmab

“All three have enormous potential, but what is important for me, is that they validate the platform. We now have five commercial agreements against the background of the platform and more than 75 percent of the internal pipeline is based on the technology, so it is profoundly important for Genmab’s future.”

Those were the optimistic and, as per usual, slightly bombastic words from Genmab’s CEO, Jan van de Winkel, back in May when he told MedWatch about the biotech’s DuoBody platform and the partnerships it has struck for it.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Johnson & Johnson misser forventningerne til salget

Selvom der er blevet solgt utallige Johnson & Johnson-vacciner mod covid-19, og Genmab-midlet Darzalex også har spædet godt til i kassen, så præsterer selskabet dårligere end analytikerne ventede i tredje kvartal.

Relaterede

Trial banner

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier